French Govt Has The Chance To Act Now To Boost Pharma Prospects, Says Industry Body
Sales growth is slowing, innovation is being impaired, and prices remain constrained in France, says the industry body Leem. It has called on the government to take urgent action to remedy the situation.
You may also be interested in...
French Pharma Industry Lays Out Wishlist For New Government, Proposes Five-Year Pact
The French pharmaceutical industry association is cautiously optimistic that the new government will take a longer-term view of the industry’s contribution to healthcare, and has proposed a pact setting out the relations between the industry and the state.
EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul
The latest delay to the European Commission’s proposals for revising the EU medicines legislation has caused consternation among members of the European Parliament who do not believe that the hold-up is due simply to a “busy agenda” at the commission.
NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.